GLPG0187

• CAT Number: I006969
• CAS Number: 1320346-97-1
• Molecular Formula: C29H37N7O5S
• Molecular Weight: 595.71
• Purity: ≥95%
• Synonyms: GLPG0187; GLPG 0187; GLPG-0187;(S)-3-((2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-((4-methoxyphenyl)sulfonamido)propanoic acid.
• Target: Integrin
• Solubility: Soluble in DMSO, not in water
• Storage: -20°C
• IUPAC Name: (2S)-3-[[2,5-dimethyl-6-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl]pyrimidin-4-yl]amino]-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid
• InChI: InChI=1S/C29H37N7O5S/c1-18-26(31-17-25(29(37)38)35-42(39,40)23-9-7-22(41-3)8-10-23)32-19(2)33-28(18)36-15-12-20(13-16-36)24-11-6-21-5-4-14-30-27(21)34-24/h6-11,20,25,35H,4-5,12-17H2,1-3H3,(H,30,34)(H,37,38)(H,31,32,33)/t25-/m0/s1
• InChIKey: CXHCNOMGODVIKB-VWLOTQADSA-N
• SMILES: CC1=C(N=C(N=C1N2CCC(CC2)C3=NC4=C(CCCN4)C=C3)C)NC[C@@H](C(=O)O)NS(=O)(=O)C5=CC=C(C=C5)OC

GLPG0187(CAT: I006969) is a potent and selective integrin receptor antagonist, designed to inhibit multiple integrins, including αvβ3, αvβ5, and α5β1. By targeting these integrins, it disrupts cell adhesion, migration, and signaling pathways associated with tumor progression, angiogenesis, and metastasis. GLPG0187 has shown promising anticancer activity in preclinical studies, making it a valuable tool for oncology research. Its mechanism also supports investigations into fibrosis and other integrin-mediated diseases, positioning it as a candidate for therapeutic development targeting integrin-related pathologies.